Monitoring coagulation and the clinical effects of recombinant factor VIIa |
| |
| Institution: | 1. Haemostasis Research Group, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James''s Hospital, Trinity College Dublin, Dublin, Ireland;2. Department of Molecular Cell Biology, VUMC, Vrije Universiteit, Amsterdam, the Netherlands;3. Inflammation and Immunity Research Group, Institute of Molecular Medicine, St James''s Hospital, Trinity College Dublin, Dublin, Ireland;4. Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland;5. National Children''s Research Centre, Our Lady''s Children''s Hospital, Crumlin, Dublin, Ireland;6. National Centre for Hereditary Coagulation Disorders, St James''s Hospital, Dublin, Ireland;1. Surgical Research Laboratory, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands;2. Department of Clinical Chemistry and Haematology, University of Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands;1. Einthoven Laboratory for Experimental Vascular Medicine, Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands;2. Center for Bleeding Disorders, Department of Heart and Vessels, Careggi University Hospital, Florence, Italy;1. Peking University People''s Hospital, Peking University Institute of Haematology, Beijing, P.R.C.;2. Department of haematology, West China Hospital, West China School of Clinical Medicine, Sichuan University, Chengdu, Sichuan, P.R.C.;3. Department of haematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P.R.C.;4. Department of haematology, Beijing Hospital, Beijing, P.R.C.;5. Department of haematology, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, P.R.C.;1. Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA;2. School of Medicine, University of Colorado, Aurora, Colorado, USA;3. Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA |
| |
| Abstract: | Accurately monitoring hemostasis in patients with coagulation disorders is vital in order to allow physicians to optimize anticoagulant therapy and deliver effective patient management. Traditional assays, based on the measurement of the time to first evidence of clot formation, fail to describe the kinetics of clot production that ultimately define the quality of the final clot. This review describes the technologies that have been developed to accurately describe and monitor the kinetics of clot formation. Using clinical examples, the utility of these technologies is assessed and conclusions drawn about the most useful diagnostic measures for monitoring hemostasis. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
